Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients

NCT05637905 | Unknown

• 1 other identifier: MCP-1
• Study Type: observational
• Target: 44
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction .
2. 2.Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .

Conditions

Psoriatic Arthritis

Outcome Measures

Primary Outcomes (1)

• MCP-1

  :Evaluate serum levels of monocyte chemoattractant protein-1(MCP-1) in relation to echocardiographic changes in patient with psoriatic arthritis.

  two month

Secondary Outcomes (1)

• Echocardiography

  two month

Study Arms (2)

psoriatic arthritis patients group

health control group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

psoriatic arthritis patients with or without clinically cardiovascular affaction

You may qualify if:

• PsA patients (age ≥ 18years) who fulfilled the CASPAR classification criteria\[15\]for psoriatic arthritis

You may not qualify if:

• PsA patients with
• infection.
• bone marrow disorders.
• other autoimmune diseases.
• diabetes.
• hypertention .
• hyperlipidemia.
• liver diseases.
• renal diseases.

Sponsors & Collaborators

• Assiut University: lead

Related Links

• 1.V.Chandran,F.Abji,A.V. Perruccio et al.,"Serum-basedsoluble markers difffferentiate psoriatic arthritis from osteoarthritis," Annals of the Rheumatic Diseases,vol.78, no.6, pp.796-801,2019.
• A. L. Carvalho and C. M. Hedrich, "The molecular pathophysiology of psoriatic arthritis-the complex interplay between genetic predisposition, epigenetics factors, and the microbiome," Frontiers in Molecular Biosciences, vol. 8, p. 662047, 2021.
• A. B. Gottlieb and J. F. Merola, "Axial psoriatic arthritis: an update for dermatologists," Journal of the American Academy of Dermatology, vol. 84, no. 1, pp. 92-101, 2021
• Lories RJ, de Vlam K. Is psoriatic arthritis a result of abnormalities in acquired or innate immunity? Curr Rheumatol Rep 2012; 14: 375-382.
• .Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-12
• Risk Reclassification According to Cardiovascular Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients
• A. Rana, V. K. Mahajan, K. S. Mehta et al., "Cardiomyopathy and echocardiographic abnormalities in Indian patients with psoriasis: results of a pilot study," International Journal of Clinical Practice, vol. 75, no. 3, p. e13756, 2021.
• P. S. Pagel, J. N. Tawil, B. T. Boettcher et al., "Heart failure with preserved ejection fraction: a comprehensive review and update of diagnosis,pathophysiology, treatment, and perioperative implications," Journal of Cardiothoracic and Vascular Anesthes
• .E. L. Potter, S. Ramkumar, H. Kawakami et al., "Association of asymptomatic diastolic dysfunction assessed by left atrial strain with incident heart failure,"JACC: Cardiovascular Imaging, vol. 13, no. 11, pp. 2316-2326, 2020.
• Lin, V. Kakkar, and X. Lu, "Impact of MCP -1 in atherosclerosis," Current Pharmaceutical Design, vol. 20, no. 28, pp. 4580-4588, 2014.
• C. Papadopoulou, V. Corrigall, P. R. Taylor, and R. N. Poston, "The role of the chemokines MCP-1, GRO-α, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques," Cytokine, vol. 43, no. 2, pp. 181-186, 2008.
• P. Aukrust, B. Halvorsen, A. Yndestad et al., "Chemokines and cardiovascular risk," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 11, pp. 1909-1919
• D. E. Furst and J. S. Louie, "Targeting inflammatory pathways in axial spondyloarthritis," Arthritis Research \& Therapy, vol. 21, no. 1, p. 135, 2019.
• Y. R. Woo, C. J. Park, H. Kang, and J. E. Kim, "The risk of systemic diseases in those with psoriasis and psoriatic arthritis:from mechanisms to clinic," International Journal of Molecular Sciences, vol. 21, no. 19, p. 7041, 2020.
• .Moll JM, Wright V Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.CrossRefPubMedGoogle Scholar.

MeSH Terms

Conditions

Arthritis, Psoriatic

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Eman Abass, doctor

  Assiut University

  STUDY DIRECTOR

• Mohamed Raouf, doctor

  Assiut University

  STUDY DIRECTOR

• Esraa Ahmed, doctor

  Assiut University

  STUDY DIRECTOR

Central Study Contacts

Amira Anas, Master

CONTACT

01066633924; amiraanas60@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: doctor

Study Record Dates

• First Submitted: November 25, 2022
• First Posted: December 6, 2022
• Study Start: January 1, 2023
• Primary Completion: March 1, 2023
• Study Completion: June 1, 2025
• Last Updated: December 6, 2022

Record last verified: 2022-11